P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
A. Russell-Smith,
R. Shah,
A. Silverstein,
A. Petrilla,
B. Leinwand,
D. Norris,
A. Schroeder
Affiliations
A. Russell-Smith
1 Pfizer R&D UK Ltd, Sandwich, United Kingdom
R. Shah
2 Pfizer Inc., New York
A. Silverstein
3 Inovalon
A. Petrilla
3 Inovalon
B. Leinwand
3 Inovalon
D. Norris
3 Inovalon
A. Schroeder
4 Avalere Health, Washington, United States of America
